Current use of active surveillance for localized prostate cancer: A nationwide survey in Japan

International Journal of Urology

Volumn 22, Issue 8, 2015, Pages 754-759

  Mitsuzuka, Koji ^a   Koga, Hirofumi ^b   Sugimoto, Mikio ^c   Arai, Yoichi ^a   Ohyama, Chikara ^d   Kakehi, Yoshiyuki ^c   Naito, Seiji ^e  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HARASANSHIN HOSPITAL   (Japan)

^c KAGAWA UNIVERSITY   (Japan)

^d HIROSAKI UNIVERSITY   (Japan)

^e KYUSHU UNIVERSITY   (Japan)

Author keywords

Active surveillance; Biopsy; Indication; Prostate cancer; Questionnaire

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER LOCALIZATION; FOLLOW UP; GENERAL HOSPITAL; HEALTH SURVEY; HUMAN; JAPAN; JAPANESE (PEOPLE); LOW RISK POPULATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; QUESTIONNAIRE; REPEAT PROCEDURE; UNIVERSITY HOSPITAL; UROLOGIST; WORK EXPERIENCE; BIOPSY; CLINICAL TRIAL; DISEASE COURSE; EARLY CANCER DIAGNOSIS; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROCEDURES; PROSTATE; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDY; VERY ELDERLY; WATCHFUL WAITING;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; HUMANS; JAPAN; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PROSTATE; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVEYS AND QUESTIONNAIRES; WATCHFUL WAITING;

EID: 84937976595     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.12813     Document Type: Article

References (29)

1. Center for Cancer Control and Information Services NCC, Japan. [Cited 1 Sept 2014.] Available from URL: http://ganjoho.jp/public/statistics/pub/statistics01.html
2. Bul M, Zhu X, Valdagni R et al. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur. Urol. 2013; 63: 597-603.
3. Thomsen FB, Brasso K, Klotz LH, Røder MA, Berg KD Iversen P. Active surveillance for clinically localized prostate cancer--a systematic review. J. Surg. Oncol. 2014; 109: 830-5.
4. Kakehi Y, Kamoto T, Shiraishi T et al. Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer. Jpn. J. Clin. Oncol. 2008; 38: 122-8.
5. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J. Clin. Oncol. 2010; 28: 126-31.
6. Dall'Era MA, Konety BR, Cowan JE et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 2008; 112: 2664-70.
7. Tosoian JJ, Trock BJ, Landis P et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J. Clin. Oncol. 2011; 29: 2185-90.
8. Mohler JL, Kantoff PW, Armstrong AJ et al. Prostate cancer, version 2.2014. J. Natl. Compr. Canc. Netw. 2014; 12: 686-718.
9. European Association of Urology. Guidelines on Prostate Cancer 2014. [Cited 1 Sept 2014.] Available from URL: http://uroweb.org/guideline/prostate-cancer/
10. Mitsuzuka K, Narita S, Koie T et al. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria. BJU Int. 2013; 111: 914-20.
11. Parker C. Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol. 2004; 5: 101-6.
12. Womble PR, Dixon MW, Linsell SM et al. Infection Related Hospitalizations after Prostate Biopsy in a Statewide Quality Improvement Collaborative. J. Urol. 2014; 191: 1787-92.
13. Loeb S, Vellekoop A, Ahmed HU et al. Systematic review of complications of prostate biopsy. Eur. Urol. 2013; 64: 876-92.
14. Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 2012; 157: 120-34.
15. Ehdaie B, Vertosick E, Spaliviero M et al. The impact of repeat biopsies on infectious complications in men with prostate cancer on active surveillance. J. Urol. 2014; 191: 660-4.
16. Loeb S, Berglund A, Stattin P. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer. J. Urol. 2013; 190: 1742-9.
17. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J. Urol. 2007; 178: S14-9.
18. Iremashvili V, Manoharan M, Lokeshwar SD, Rosenberg DL, Pan D, Soloway MS. Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients. BJU Int. 2013; 111: 396-403.
19. Ross AE, Loeb S, Landis P et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J. Clin. Oncol. 2010; 28: 2810-6.
20. Ploussard G, Durand X, Xylinas E et al. Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur. Urol. 2011; 59: 422-9.
21. Hirama H, Sugimoto M, Ito K, Shiraishi T, Kakehi Y. The impact of baseline [-2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort. J. Cancer Res. Clin. Oncol. 2014; 140: 257-63.
22. Duffield AS, Lee TK, Miyamoto H, Carter HB Epstein JI. Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails. J. Urol. 2009; 182: 2274-8.
23. Lawrentschuk N, Haider MA, Daljeet N et al. 'Prostatic evasive anterior tumours': the role of magnetic resonance imaging. BJU Int. 2010; 105: 1231-6.
24. Mullins JK, Carter HB. Multiparametric magnetic resonance imaging (MRI) and active surveillance for prostate cancer: future directions. BJU Int. 2014; 113: 844-5.
25. Volkin D, Turkbey B, Hoang AN et al. Multiparametric magnetic resonance imaging (MRI) and subsequent MRI/ultrasonography fusion-guided biopsy increase the detection of anteriorly located prostate cancers. BJU Int. 2014; 114: E43-9.
26. Moore CM, Petrides N Emberton M. Can MRI replace serial biopsies in men on active surveillance for prostate cancer? Curr. Opin. Urol. 2014; 24: 280-7.
27. Park BH, Jeon HG, Choo SH et al. Role of multiparametric 3.0-Tesla magnetic resonance imaging in patients with prostate cancer eligible for active surveillance. BJU Int. 2014; 113: 864-70.
28. Stamatakis L, Siddiqui MM, Nix JW et al. Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer. Cancer 2013; 119: 3359-66.
29. Klotz L, Vesprini D, Sethukavalan P et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J. Clin. Oncol. 2015; 33: 272-7.